-
1
-
-
0000197190
-
Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer
-
[PMID: 11957056 DOI: 10.1007/s101200050006]
-
Kim JP, Lee JH, Kim SJ, Yu HJ, Yang HK. Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer. Gastric Cancer 1998; 1: 125-133 [PMID: 11957056 DOI: 10.1007/s101200050006]
-
(1998)
Gastric Cancer
, vol.1
, pp. 125-133
-
-
Kim, J.P.1
Lee, J.H.2
Kim, S.J.3
Yu, H.J.4
Yang, H.K.5
-
2
-
-
0028316143
-
Shifting proportions of gastric adenocarcinomas
-
discussion 381-38; [PMID: 7512326 DOI: 10.1001/archsurg.1994.01420280053007]
-
Salvon-Harman JC, Cady B, Nikulasson S, Khettry U, Stone MD, Lavin P. Shifting proportions of gastric adenocarcinomas. Arch Surg 1994; 129: 381-38; discussion 381-38; [PMID: 7512326 DOI: 10.1001/archsurg.1994.01420280053007]
-
(1994)
Arch Surg
, vol.129
, pp. 381-388
-
-
Salvon-Harman, J.C.1
Cady, B.2
Nikulasson, S.3
Khettry, U.4
Stone, M.D.5
Lavin, P.6
-
3
-
-
0035818048
-
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction
-
[PMID: 11547741 DOI: 10.1056/NEJMoa010187]
-
Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730 [PMID: 11547741 DOI: 10.1056/NEJMoa010187]
-
(2001)
N Engl J Med
, vol.345
, pp. 725-730
-
-
Macdonald, J.S.1
Smalley, S.R.2
Benedetti, J.3
Hundahl, S.A.4
Estes, N.C.5
Stemmermann, G.N.6
Haller, D.G.7
Ajani, J.A.8
Gunderson, L.L.9
Jessup, J.M.10
Martenson, J.A.11
-
4
-
-
56849100975
-
Treatment of gastric cancer
-
[PMID: 19033703 DOI: 10.1159/000163075]
-
Lordick F, Ridwelski K, Al-Batran SE, Trarbach T, Schlag PM, Piso P. [Treatment of gastric cancer]. Onkologie 2008; 31 Suppl 5: 32-39 [PMID: 19033703 DOI: 10.1159/000163075]
-
(2008)
Onkologie
, vol.31
, Issue.SUPPL. 5
, pp. 32-39
-
-
Lordick, F.1
Ridwelski, K.2
Al-Batran, S.E.3
Trarbach, T.4
Schlag, P.M.5
Piso, P.6
-
5
-
-
34548337032
-
Therapeutic options in gastric cancer: Neoadjuvant chemotherapy vs postoperative chemoradiotherapy
-
discussion 1090, 1084-107; 1101, [PMID: 17910312]
-
Jackson C, Mochlinski K, Cunningham D. Therapeutic options in gastric cancer: neoadjuvant chemotherapy vs postoperative chemoradiotherapy. Oncology (Williston Park) 2007; 21: 1084-107; discussion 1090, 1084-107; 1101 [PMID: 17910312]
-
(2007)
Oncology (Williston Park)
, vol.21
, pp. 1084-1107
-
-
Jackson, C.1
Mochlinski, K.2
Cunningham, D.3
-
6
-
-
33745726677
-
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
-
[PMID: 16822992 DOI: 10.1056/NEJMoa055531]
-
Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20 [PMID: 16822992 DOI: 10.1056/NEJMoa055531]
-
(2006)
N Engl J Med
, vol.355
, pp. 11-20
-
-
Cunningham, D.1
Allum, W.H.2
Stenning, S.P.3
Thompson, J.N.4
Van de Velde, C.J.5
Nicolson, M.6
Scarffe, J.H.7
Lofts, F.J.8
Falk, S.J.9
Iveson, T.J.10
Smith, D.B.11
Langley, R.E.12
Verma, M.13
Weeden, S.14
Chua, Y.J.15
-
7
-
-
84941982813
-
Chemotherapy for advanced gastric cancer
-
[PMID: 15846694]
-
Wagner AD, Grothe W, Behl S, Kleber G, Grothey A, Haerting J, Fleig WE. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2005; (2): CD004064 [PMID: 15846694]
-
(2005)
Cochrane Database Syst Rev
, Issue.2
-
-
Wagner, A.D.1
Grothe, W.2
Behl, S.3
Kleber, G.4
Grothey, A.5
Haerting, J.6
Fleig, W.E.7
-
8
-
-
33750949065
-
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group
-
[PMID: 17075117 DOI: 10.1200/JCO.2006.06.8429]
-
Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997 [PMID: 17075117 DOI: 10.1200/JCO.2006.06.8429]
-
(2006)
J Clin Oncol
, vol.24
, pp. 4991-4997
-
-
van Cutsem, E.1
Moiseyenko, V.M.2
Tjulandin, S.3
Majlis, A.4
Constenla, M.5
Boni, C.6
Rodrigues, A.7
Fodor, M.8
Chao, Y.9
Voznyi, E.10
Risse, M.L.11
Ajani, J.A.12
-
9
-
-
63749118193
-
Capecitabine/ cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: A randomised phase III noninferiority trial
-
[PMID: 19153121 DOI: 10.1093/annonc/mdn717]
-
Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI. Capecitabine/ cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009; 20: 666-673 [PMID: 19153121 DOI: 10.1093/annonc/mdn717]
-
(2009)
Ann Oncol
, vol.20
, pp. 666-673
-
-
Kang, Y.K.1
Kang, W.K.2
Shin, D.B.3
Chen, J.4
Xiong, J.5
Wang, J.6
Lichinitser, M.7
Guan, Z.8
Khasanov, R.9
Zheng, L.10
Philco-Salas, M.11
Suarez, T.12
Santamaria, J.13
Forster, G.14
McCloud, P.I.15
-
10
-
-
14644415510
-
Can cisplatin and infused 5-fluorouracil be replaced by oxaliplatin and capecitabine in the treatment of advanced oesophagogastric cancer? The REAL 2 trial
-
[PMID: 15830568 DOI: 10.1016/j.clon.2004.12.004]
-
Chong G, Cunningham D. Can cisplatin and infused 5-fluorouracil be replaced by oxaliplatin and capecitabine in the treatment of advanced oesophagogastric cancer? The REAL 2 trial. Clin Oncol (R Coll Radiol) 2005; 17: 79-80 [PMID: 15830568 DOI: 10.1016/j.clon.2004.12.004]
-
(2005)
Clin Oncol (R Coll Radiol)
, vol.17
, pp. 79-80
-
-
Chong, G.1
Cunningham, D.2
-
11
-
-
77956262693
-
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, openlabel, randomised controlled trial
-
[PMID: 20728210 DOI: 10.1016/S0140-6736(10)61022-7]
-
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet 2010; 376: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61022-7]
-
(2010)
Lancet
, vol.376
, pp. 687-697
-
-
Bang, Y.J.1
van Cutsem, E.2
Feyereislova, A.3
Chung, H.C.4
Shen, L.5
Sawaki, A.6
Lordick, F.7
Ohtsu, A.8
Omuro, Y.9
Satoh, T.10
Aprile, G.11
Kulikov, E.12
Hill, J.13
Lehle, M.14
Rüschoff, J.15
Kang, Y.K.16
-
12
-
-
0242635713
-
Surgical outcomes of patients with gastric carcinoma: The importance of primary tumor location and microvessel invasion
-
discussion 720-77;, [PMID: 14605635 DOI: 10.1016/ S0039-6060(03)00337-4]
-
Talamonti MS, Kim SP, Yao KA, Wayne JD, Feinglass J, Bennett CL, Rao S. Surgical outcomes of patients with gastric carcinoma: the importance of primary tumor location and microvessel invasion. Surgery 2003; 134: 720-77; discussion 720-77; [PMID: 14605635 DOI: 10.1016/ S0039-6060(03)00337-4]
-
(2003)
Surgery
, vol.134
, pp. 720-777
-
-
Talamonti, M.S.1
Kim, S.P.2
Yao, K.A.3
Wayne, J.D.4
Feinglass, J.5
Bennett, C.L.6
Rao, S.7
-
13
-
-
0025172663
-
Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites
-
[PMID: 2206952]
-
Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer 1990; 62: 440-443 [PMID: 2206952]
-
(1990)
Br J Cancer
, vol.62
, pp. 440-443
-
-
Powell, J.1
McConkey, C.C.2
-
14
-
-
0030745053
-
Proximal gastric cancers resected via a transabdominal-only approach. Results and comparisons to distal adenocarcinoma of the stomach
-
discussion 683-5, [PMID: 9230808]
-
Harrison LE, Karpeh MS, Brennan MF. Proximal gastric cancers resected via a transabdominal-only approach. Results and comparisons to distal adenocarcinoma of the stomach. Ann Surg 1997; 225: 678-83; discussion 683-5 [PMID: 9230808]
-
(1997)
Ann Surg
, vol.225
, pp. 678-683
-
-
Harrison, L.E.1
Karpeh, M.S.2
Brennan, M.F.3
-
15
-
-
0026576745
-
Prognosis for surgically treated gastric cancer patients is poorer for women than men in all patients under age 50
-
[PMID: 1558797]
-
Maehara Y, Watanabe A, Kakeji Y, Emi Y, Moriguchi S, Anai H, Sugimachi K. Prognosis for surgically treated gastric cancer patients is poorer for women than men in all patients under age 50. Br J Cancer 1992; 65: 417-420 [PMID: 1558797]
-
(1992)
Br J Cancer
, vol.65
, pp. 417-420
-
-
Maehara, Y.1
Watanabe, A.2
Kakeji, Y.3
Emi, Y.4
Moriguchi, S.5
Anai, H.6
Sugimachi, K.7
-
16
-
-
14744301259
-
Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy
-
discussion 237-8, [PMID: 15726615]
-
Persiani R, D'Ugo D, Rausei S, Sermoneta D, Barone C, Pozzo C, Ricci R, La Torre G, Picciocchi A. Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy. J Surg Oncol 2005; 89: 227-36; discussion 237-8 [PMID: 15726615]
-
(2005)
J Surg Oncol
, vol.89
, pp. 227-236
-
-
Persiani, R.1
D'Ugo, D.2
Rausei, S.3
Sermoneta, D.4
Barone, C.5
Pozzo, C.6
Ricci, R.7
la Torre, G.8
Picciocchi, A.9
-
17
-
-
0029114298
-
Prognostic factors for gastric cancer influencing clinical practice
-
[PMID: 7676690]
-
Harrison JD, Fielding JW. Prognostic factors for gastric cancer influencing clinical practice. World J Surg 1995; 19: 496-500 [PMID: 7676690]
-
(1995)
World J Surg
, vol.19
, pp. 496-500
-
-
Harrison, J.D.1
Fielding, J.W.2
-
18
-
-
1042304320
-
Correlation of tumor-positive ratio and number of perigastric lymph nodes with prognosis of patients with surgically-removed gastric carcinoma
-
[PMID: 14716818]
-
Ding YB, Chen GY, Xia JG, Zang XW, Yang HY, Yang L, Liu YX. Correlation of tumor-positive ratio and number of perigastric lymph nodes with prognosis of patients with surgically-removed gastric carcinoma. World J Gastroenterol 2004; 10: 182-185 [PMID: 14716818]
-
(2004)
World J Gastroenterol
, vol.10
, pp. 182-185
-
-
Ding, Y.B.1
Chen, G.Y.2
Xia, J.G.3
Zang, X.W.4
Yang, H.Y.5
Yang, L.6
Liu, Y.X.7
-
19
-
-
0027234691
-
Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group
-
[PMID: 8402053 DOI: 10.1002/bjs.1800800829]
-
Siewert JR, Böttcher K, Roder JD, Busch R, Hermanek P, Meyer HJ. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. Br J Surg 1993; 80: 1015-1018 [PMID: 8402053 DOI: 10.1002/bjs.1800800829]
-
(1993)
Br J Surg
, vol.80
, pp. 1015-1018
-
-
Siewert, J.R.1
Böttcher, K.2
Roder, J.D.3
Busch, R.4
Hermanek, P.5
Meyer, H.J.6
-
20
-
-
0023243860
-
The most important prognostic factors cancer patients: A study using univariate and multivariate analyses
-
[DOI: 10.3109/003655287 09091021]
-
Maruyama K. The most important prognostic factors cancer patients: a study using univariate and multivariate analyses. Scand J Gastroenterol 1987; 22: 63-68 [DOI: 10.3109/003655287 09091021]
-
(1987)
Scand J Gastroenterol
, vol.22
, pp. 63-68
-
-
Maruyama, K.1
-
21
-
-
12644292106
-
The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification
-
[PMID: 14320675]
-
Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49 [PMID: 14320675]
-
(1965)
Acta Pathol Microbiol Scand
, vol.64
, pp. 31-49
-
-
Lauren, P.1
-
22
-
-
77449140153
-
The GYMSSA trial: A prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone
-
[PMID: 20030854 DOI: 10.1186/1745-6215-10-12 1]
-
Kerkar SP, Kemp CD, Duffy A, Kammula US, Schrump DS, Kwong KF, Quezado M, Goldspiel BR, Venkatesan A, Berger A, Walker M, Toomey MA, Steinberg SM, Giaccone G, Rosenberg SA, Avital I. The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone. Trials 2009; 10: 121 [PMID: 20030854 DOI: 10.1186/1745-6215-10-12 1]
-
(2009)
Trials
, vol.10
, pp. 121
-
-
Kerkar, S.P.1
Kemp, C.D.2
Duffy, A.3
Kammula, U.S.4
Schrump, D.S.5
Kwong, K.F.6
Quezado, M.7
Goldspiel, B.R.8
Venkatesan, A.9
Berger, A.10
Walker, M.11
Toomey, M.A.12
Steinberg, S.M.13
Giaccone, G.14
Rosenberg, S.A.15
Avital, I.16
-
23
-
-
78149469874
-
Pulmonary resection for metastatic gastric cancer
-
[PMID: 20881648 DOI: 10.1097/JTO.0b013e3181ed3514]
-
Kemp CD, Kitano M, Kerkar S, Ripley RT, Marquardt JU, Schrump DS, Avital I. Pulmonary resection for metastatic gastric cancer. J Thorac Oncol 2010; 5: 1796-1805 [PMID: 20881648 DOI: 10.1097/JTO.0b013e3181ed3514]
-
(2010)
J Thorac Oncol
, vol.5
, pp. 1796-1805
-
-
Kemp, C.D.1
Kitano, M.2
Kerkar, S.3
Ripley, R.T.4
Marquardt, J.U.5
Schrump, D.S.6
Avital, I.7
-
24
-
-
0018949428
-
Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group
-
[PMID: 7424938 DOI: 10.1016/ S0149-2918(05)80001-3]
-
Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO, Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlia C, Rosenbaum C, Silverstein MN, Skeel RT, Sponzo RW, Tormey DC. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980; 69: 491-497 [PMID: 7424938 DOI: 10.1016/ S0149-2918(05)80001-3]
-
(1980)
Am J Med
, vol.69
, pp. 491-497
-
-
Dewys, W.D.1
Begg, C.2
Lavin, P.T.3
Band, P.R.4
Bennett, J.M.5
Bertino, J.R.6
Cohen, M.H.7
Douglass, H.O.8
Engstrom, P.F.9
Ezdinli, E.Z.10
Horton, J.11
Johnson, G.J.12
Moertel, C.G.13
Oken, M.M.14
Perlia, C.15
Rosenbaum, C.16
Silverstein, M.N.17
Skeel, R.T.18
Sponzo, R.W.19
Tormey, D.C.20
more..
-
25
-
-
0028783410
-
Prognostic value of combination assays for CEA and CA 19-9 in gastric cancer
-
[PMID: 7478435 DOI: 10.1159/000227515]
-
Ikeda Y, Oomori H, Koyanagi N, Mori M, Kamakura T, Minagawa S, Tateishi H, Sugimachi K. Prognostic value of combination assays for CEA and CA 19-9 in gastric cancer. Oncology 1995; 52: 483-486 [PMID: 7478435 DOI: 10.1159/000227515]
-
(1995)
Oncology
, vol.52
, pp. 483-486
-
-
Ikeda, Y.1
Oomori, H.2
Koyanagi, N.3
Mori, M.4
Kamakura, T.5
Minagawa, S.6
Tateishi, H.7
Sugimachi, K.8
-
26
-
-
0026550087
-
Tumour markers CA 19-9 and CA 50 in digestive tract malignancies
-
[PMID: 1502477 DOI: 10.3109/00365529208999944]
-
Haglund C, Roberts PJ, Jalanko H, Kuusela P. Tumour markers CA 19-9 and CA 50 in digestive tract malignancies. Scand J Gastroenterol 1992; 27: 169-174 [PMID: 1502477 DOI: 10.3109/00365529208999944]
-
(1992)
Scand J Gastroenterol
, vol.27
, pp. 169-174
-
-
Haglund, C.1
Roberts, P.J.2
Jalanko, H.3
Kuusela, P.4
-
27
-
-
0023598081
-
The clinical usefulness of preoperative CEA determination in gastric cancer
-
[PMID: 3430898 DOI: 10.1007/BF02470632]
-
Koga T, Kano T, Souda K, Oka N, Inokuchi K. The clinical usefulness of preoperative CEA determination in gastric cancer. Jpn J Surg 1987; 17: 342-347 [PMID: 3430898 DOI: 10.1007/BF02470632]
-
(1987)
Jpn J Surg
, vol.17
, pp. 342-347
-
-
Koga, T.1
Kano, T.2
Souda, K.3
Oka, N.4
Inokuchi, K.5
-
28
-
-
84867066324
-
Long-term survivors of gastric cancer: A California population-based study
-
[PMID: 22949151 DOI: 10.1200/JCO.2011.35.8028]
-
Kunz PL, Gubens M, Fisher GA, Ford JM, Lichtensztajn DY, Clarke CA. Long-term survivors of gastric cancer: a California population-based study. J Clin Oncol 2012; 30: 3507-3515 [PMID: 22949151 DOI: 10.1200/JCO.2011.35.8028]
-
(2012)
J Clin Oncol
, vol.30
, pp. 3507-3515
-
-
Kunz, P.L.1
Gubens, M.2
Fisher, G.A.3
Ford, J.M.4
Lichtensztajn, D.Y.5
Clarke, C.A.6
-
29
-
-
33745547767
-
Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data
-
[PMID: 16782930 DOI: 10.1200/JCO.2005.05.0245]
-
Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-2909 [PMID: 16782930 DOI: 10.1200/JCO.2005.05.0245]
-
(2006)
J Clin Oncol
, vol.24
, pp. 2903-2909
-
-
Wagner, A.D.1
Grothe, W.2
Haerting, J.3
Kleber, G.4
Grothey, A.5
Fleig, W.E.6
-
30
-
-
70349937924
-
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)
-
[PMID: 19773760 DOI: 10.1038/sj.bjc.6605319]
-
Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Cascinu S, Rojas Llimpe FL, Stella G, Schinzari G, Artale S, Mutri V, Giaquinta S, Giannetta L, Bardelli A, Martoni AA. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer 2009; 101: 1261-1268 [PMID: 19773760 DOI: 10.1038/sj.bjc.6605319]
-
(2009)
Br J Cancer
, vol.101
, pp. 1261-1268
-
-
Pinto, C.1
Di Fabio, F.2
Barone, C.3
Siena, S.4
Falcone, A.5
Cascinu, S.6
Rojas Llimpe, F.L.7
Stella, G.8
Schinzari, G.9
Artale, S.10
Mutri, V.11
Giaquinta, S.12
Giannetta, L.13
Bardelli, A.14
Martoni, A.A.15
-
31
-
-
80054057131
-
Southwest Oncology Group study S0413: A phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer
-
[PMID: 21415234 DOI: 10.1093/annonc/mdr021]
-
Iqbal S, Goldman B, Fenoglio-Preiser CM, Lenz HJ, Zhang W, Danenberg KD, Shibata SI, Blanke CD. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol 2011; 22: 2610-2615 [PMID: 21415234 DOI: 10.1093/annonc/mdr021]
-
(2011)
Ann Oncol
, vol.22
, pp. 2610-2615
-
-
Iqbal, S.1
Goldman, B.2
Fenoglio-Preiser, C.M.3
Lenz, H.J.4
Zhang, W.5
Danenberg, K.D.6
Shibata, S.I.7
Blanke, C.D.8
-
32
-
-
80052439302
-
Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastrooesophageal junction
-
[PMID: 21811258 DOI: 10.1038/bjc.2011.280]
-
Wainberg ZA, Lin LS, DiCarlo B, Dao KM, Patel R, Park DJ, Wang HJ, Elashoff R, Ryba N, Hecht JR. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastrooesophageal junction. Br J Cancer 2011; 105: 760-765 [PMID: 21811258 DOI: 10.1038/bjc.2011.280]
-
(2011)
Br J Cancer
, vol.105
, pp. 760-765
-
-
Wainberg, Z.A.1
Lin, L.S.2
DiCarlo, B.3
Dao, K.M.4
Patel, R.5
Park, D.J.6
Wang, H.J.7
Elashoff, R.8
Ryba, N.9
Hecht, J.R.10
-
33
-
-
33846629672
-
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma
-
[PMID: 17114652 DOI: 10.1200/ JCO.2006.08.0887]
-
Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK, Kelsen DP. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24: 5201-5206 [PMID: 17114652 DOI: 10.1200/ JCO.2006.08.0887]
-
(2006)
J Clin Oncol
, vol.24
, pp. 5201-5206
-
-
Shah, M.A.1
Ramanathan, R.K.2
Ilson, D.H.3
Levnor, A.4
D'Adamo, D.5
O'Reilly, E.6
Tse, A.7
Trocola, R.8
Schwartz, L.9
Capanu, M.10
Schwartz, G.K.11
Kelsen, D.P.12
-
34
-
-
79958803154
-
An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer
-
[PMID: 21561763 DOI: 10.1016/ j.ejca.2011.04.006]
-
Moehler M, Mueller A, Hartmann JT, Ebert MP, Al-Batran SE, Reimer P, Weihrauch M, Lordick F, Trarbach T, Biesterfeld S, Kabisch M, Wachtlin D, Galle PR. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer 2011; 47: 1511-1520 [PMID: 21561763 DOI: 10.1016/ j.ejca.2011.04.006]
-
(2011)
Eur J Cancer
, vol.47
, pp. 1511-1520
-
-
Moehler, M.1
Mueller, A.2
Hartmann, J.T.3
Ebert, M.P.4
Al-Batran, S.E.5
Reimer, P.6
Weihrauch, M.7
Lordick, F.8
Trarbach, T.9
Biesterfeld, S.10
Kabisch, M.11
Wachtlin, D.12
Galle, P.R.13
-
35
-
-
77951635629
-
Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer
-
[PMID: 20231677 DOI: 10.1200/ JCO.2009.26.29]
-
Doi T, Muro K, Boku N, Yamada Y, Nishina T, Takiuchi H, Komatsu Y, Hamamoto Y, Ohno N, Fujita Y, Robson M, Ohtsu A. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 2010; 28: 1904-1910 [PMID: 20231677 DOI: 10.1200/ JCO.2009.26.29]
-
(2010)
J Clin Oncol
, vol.28
, pp. 1904-1910
-
-
Doi, T.1
Muro, K.2
Boku, N.3
Yamada, Y.4
Nishina, T.5
Takiuchi, H.6
Komatsu, Y.7
Hamamoto, Y.8
Ohno, N.9
Fujita, Y.10
Robson, M.11
Ohtsu, A.12
|